We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $113M
1-Year Est. Return 73.91%
This Fund
S&P 500
This Quarter Est. Return
+9.13%
1 Year Est. Return
+73.91%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$566M
Cap. Flow
-$573M
Cap. Flow %
-509.53%
Top 10 Hldgs %
59.57%
Holding
143
New
38
Increased
22
Reduced
20
Closed
61

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$9.34M
2
ASX icon
ASE Group
ASX
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.84M
4
AXSM icon
Axsome Therapeutics
AXSM
+$2.47M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.39M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$82.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$71.3M
3
MSFT icon
Microsoft
MSFT
+$70.1M
4
C icon
Citigroup
C
+$54.1M
5
HD icon
Home Depot
HD
+$54M

Sector Composition

Rank Sector Weight
1 Healthcare 42.66%
2 Communication Services 8.03%
3 Technology 3.81%
4 Financials 0.8%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIOA
51
BioAge Labs
BIOA
$985M
$364K 0.32%
+20,796
New +$400K
APGE icon
52
Apogee Therapeutics
APGE
$10.1B
$337K 0.3%
4,007
-2,317
-37% -$168K
IBRX icon
53
ImmunityBio
IBRX
$7.8B
$315K 0.28%
+41,005
New +$281K
UTHR icon
54
United Therapeutics
UTHR
$22.5B
$313K 0.28%
+527
New +$262K
DYN icon
55
Dyne Therapeutics
DYN
$3.76B
$312K 0.28%
17,213
+2,830
+20% +$48.8K
SYRE icon
56
Spyre Therapeutics
SYRE
$8.17B
$310K 0.28%
6,140
-7,584
-55% -$286K
TYRA icon
57
Tyra Biosciences
TYRA
$1.88B
$309K 0.27%
+8,075
New +$261K
XLF icon
58
State Street Financial Select Sector SPDR ETF
XLF
$54.8B
$306K 0.27%
6,200
-17,200
-74% -$896K
SPY icon
59
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$273K 0.24%
+420
New +$286K
ALMS
60
Alumis Inc
ALMS
$3.47B
$265K 0.24%
+12,031
New +$301K
ORKA
61
Oruka Therapeutics
ORKA
$5.01B
$252K 0.22%
+5,147
New +$179K
EQH icon
62
Equitable Holdings
EQH
$13.4B
$252K 0.22%
+6,794
New +$291K
FLTW icon
63
Franklin FTSE Taiwan ETF
FLTW
$2.74B
$252K 0.22%
+3,700
New +$251K
SMMT icon
64
Summit Therapeutics
SMMT
$10.7B
$230K 0.2%
+12,136
New +$196K
NVST icon
65
Envista
NVST
$4.39B
$228K 0.2%
9,001
-5,699
-39% -$148K
CGON icon
66
CG Oncology
CGON
$6.13B
$228K 0.2%
+3,370
New +$191K
DXCM icon
67
DexCom
DXCM
$30.1B
$228K 0.2%
+3,628
New +$253K
NKTR icon
68
Nektar Therapeutics
NKTR
$2.27B
$204K 0.18%
2,830
-2,097
-43% -$119K
GPCR icon
69
Structure Therapeutics
GPCR
$3.27B
$202K 0.18%
+4,190
New +$287K
VSTM icon
70
Verastem
VSTM
$507M
$192K 0.17%
+36,170
New +$223K
GDX icon
71
VanEck Gold Miners ETF
GDX
$21.8B
$184K 0.16%
2,000
-4,200
-68% -$414K
CLYM
72
Climb Bio
CLYM
$720M
$168K 0.15%
+24,590
New +$142K
UAMY icon
73
United States Antimony
UAMY
$790M
$99.7K 0.09%
+11,426
New +$99.6K
GOOG icon
74
Alphabet (Google) Class C
GOOG
$4.32T
$86.1K 0.08%
300
+100
+50% +$31.4K
IOVA icon
75
Iovance Biotherapeutics
IOVA
$2.08B
$69.4K 0.06%
+19,760
New +$63.2K
1 2
3
4 5

Similar funds

MWP
Momentum Wealth Planning Estero, Florida $113M AUM 26.08% 1-Year Est. Return
AIC
Argus Investors Counsel New York $112M AUM 25.83% 1-Year Est. Return
OP
Oath Planning Tulsa, Oklahoma $113M AUM
VCM
Veradace Capital Management Dallas, Texas $112M AUM
TBNY
Trustco Bank (New York) Albany, New York $113M AUM 34.59% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return
PFS
Professional Financial Solutions Falls Chruch, Virginia $112M AUM
UOWF
University of Wisconsin Foundation Madison, Wisconsin $113M AUM 23.15% 1-Year Est. Return

Arrowpoint Investment Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Arrowpoint Investment Partners held 143 positions worth $113M, down 83% from $679M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Arrowpoint Investment Partners withdrew a net $573M in Q1 2026, closing 61 positions and reducing 20 holdings. Its most notable exit was NVIDIA, an estimated $82.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 18% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Arrowpoint Investment Partners opened a new position in ASE Group worth $3.89M.

  • Arrowpoint Investment Partners's largest Q1 2026 buy was ASE Group: 179,512 shares worth $3.89M.
  • Arrowpoint Investment Partners added most to Alphabet (Google) Class A in Q1 2026, an estimated $9.34M increase.
  • Arrowpoint Investment Partners's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $71.3M.
  • Arrowpoint Investment Partners fully exited NVIDIA in Q1 2026, selling an estimated $82.5M.
  • Arrowpoint Investment Partners's ten largest holdings make up 60% of its $113M portfolio in Q1 2026.
  • Arrowpoint Investment Partners opened 38 new positions and closed 61 in Q1 2026.
  • Arrowpoint Investment Partners's portfolio value fell 83% quarter-over-quarter to $113M.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.